Scripps Translational Science Institute

The Economist: “Personal genetic-testing industry is under fire, but happier days lie ahead”

So far, direct-to-consumer genetics firms have struggled to make money, according to an Aug. 12, 2010 article in The Economist. Dr. Eric Topol, STSI’s Director, is quoted as estimating that only about 100,000 people have paid for these genetic tests.

Read More…

Docs falling behind in race to help patients with genetics

Dr. Eric Topol’s commentary, “Pharmacy Benefit Managers, Pharmacies, and Pharmacogenomic Testing: Prescription for Progress?”, in the Aug. 11, 2010 issue of Science Translational Medicine, generated several news articles as well as a San Diego Union Tribune essay by the STSI Director. “While physicians and the life science industry have done little to advance the use of testing for drug-gene interactions, now the pharmacy benefit managers (PBMs) Medco and CVS/Caremark, which collectively administer the employer prescription plans for nearly 100 million Americans, are stepping up,” Dr. Topol wrote in the essay.

Read More…

Scripps Genomic Medicine partners with Sanofi-aventis to advance individualized medicine

Sanofi-aventis and Scripps Genomic Medicine announced a strategic alliance to advance research and development initiatives in the field of individualized medicine.  Eric Topol, M.D., Chief Academic Officer of Scripps Health and Director of Scripps Genomic Medicine and the Scripps Translational Science Institute, said,  “The partnership aims to foster an environment of open scientific exchange in genomic medicine that we hope will translate to new discoveries to benefit patients while establishing a collaborative approach to drug development.”

Read More…

Fox Business News interview with Dr. Eric Topol

Read More…

Dr. Eric Topol elected to California Healthcare Institute Board of Directors

Read More…